Financing channel feed

Phar­varis soars on mid-stage da­ta for se­vere swelling con­di­tion, rais­es $300M

Last year
R&D

Scoop: In­fec­tious dis­ease biotech eyes $25M Se­ries A to ad­vance an­ti­body for chron­ic lung in­fec­tion

Last year
R&D

Ex­clu­sive: Gary Glick’s Odyssey rais­es $101M Se­ries C as first im­munol­o­gy drugs ap­proach the clin­ic

Last year

Seis­mic rais­es $121M to en­ter im­munol­o­gy space spot­light­ed by ar­genx, Im­muno­vant and oth­ers

Last year
R&D

Ex­clu­sive: San Diego biotech rais­es $11.7M to use cells as tar­get­ed de­liv­ery ves­sels for ge­net­ic med­i­cines

Last year
Startups

ARCH-al­lied AN Ven­ture Part­ners rais­es $200M to build biotechs out of re­search from Japan

Last year
Startups

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug dis­cov­ery

Last year
Startups
China

Cell man­u­fac­tur­ing com­pa­ny rais­es $19M Se­ries A to in­crease ca­pac­i­ty, staff num­bers 

Last year
Manufacturing

Ex­clu­sive: No­vo foun­da­tion's growth arm is mak­ing an in­vest­ment push in­to health­care, ex­pand­ing be­yond life sci­ences

Last year
Health Tech

Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Last year
R&D

Health tech stands out as a top area for ear­ly-stage VC fund­ing in Q3

Last year
Health Tech

Ar­ri­vo bags $45M Se­ries B to fund ma­jor de­pres­sion late-stage test and PhII-ready pan­cre­ati­tis as­set

Last year
R&D

Verve rais­es $148M via pub­lic stock of­fer­ing, pri­vate place­ment with Eli Lil­ly (cor­rect­ed)

Last year

Ear­ly-stage health­care star­tups are fac­ing a fund­ing cliff

Last year
Health Tech

Eu­ro­pean AI start­up rais­es $24M for pro­tein de­sign soft­ware ser­vice

Last year
AI

Arv­inas gets $350M boost from in­vestors to ex­tend run­way in­to 2027

Last year

Khosla Ven­tures leads $38M seed round for organoid start­up Vivo­dyne

Last year
AI

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

Last year
Startups
R&D

For­mer col­lege room­mates com­bine health and tech back­grounds to raise $58M for new fund

Last year
Health Tech

Obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics files for IPO

Last year
Startups

Biotech’s IPO out­look for the rest of the year sours in wake of war, broad­er in­dus­try strug­gles

Last year
Startups

Scoop: Rakuten Med­ical tar­gets year-end close for $100M+ Se­ries E to fund pho­toim­munother­a­py pipeline: #Jef­feries23

Last year
R&D

Scoop: Cell­Prothera eyes $30M round for PhI­II tri­al of cell ther­a­py for heart at­tacks: #Jef­feries23

Last year
Cell/Gene Tx

NMD Phar­ma se­cures €75M from in­sid­ers for three PhII tri­als in neu­ro­mus­cu­lar dis­or­ders

Last year
Startups
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times